ABSTRACT
SARS-CoV-2 is evolved into eight fundamental clades where four (G, GH, GR, and GV) are globally prevalent in 2020. How the featured co-occurring mutations of these clades are linked with viral fitness is the main question here and we thus proposed a hypothetical model using in silico approach to explain the plausible epistatic effects of those mutations on viral replication and transmission. Molecular docking and dynamics analyses showed the higher infectiousness of a spike mutant through more favorable binding of G614 with the elastase-2. RdRp mutation p.P323L significantly increased genome-wide mutations (p<0.0001) since more flexible RdRp (mutated)-NSP8 interaction may accelerate replication. Superior RNA stability and structural variation at NSP3:C241T might impact protein and/or RNA interactions. Another silent 5’UTR:C241T mutation might affect translational efficiency and viral packaging. These four G-clade-featured co-occurring mutations might increase viral replication. Sentinel GH-clade ORF3a:p.Q57H constricted ion-channel through inter-transmembrane-domain interaction of cysteine(C81)-histidine(H57) and GR-clade N:p.RG203-204KR would stabilize RNA interaction by a more flexible and hypo-phosphorylated SR-rich region. GV-clade viruses seemingly gained the evolutionary advantage of the confounding factors; nevertheless, N:p.A220V might modulate RNA binding with no phenotypic effect. Our hypothetical model needs further retrospective and prospective studies to understand detailed molecular events featuring the fitness of SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We get no funds to carry out this research work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our University (Jashore University of Science and Technology) has provided ethical permission to do the work. However, this is a dry lab work.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We included this reference and discussed it whenever related to our work in every aspect. We also found another report from PNAS (https://www.pnas.org/content/118/29/e2104241118) that showed epistatic network-based interactions. Thus, we included both works in our introduction and discussion part on epistasis. We included the literature where the selection analysis was already performed on these mutations. Also, a site developed by a renowned bioinformatician (https://observablehq.com/@spond/evolutionary-annotation-of-sars-cov-2-covid-19-genomes-enab?collection=@spond/sars-cov-2) contains all necessary information for selection analysis. we changed the color contrast of one of the figures (figure 7a now) to make it easily observable to the readers. We deleted the epidemiology part since a similar study was published elsewhere (https://www.nature.com/articles/s41598-021-87713-x) and GISAID had the graphs as well on their site. We now focused on the epistasis part mainly and did not correlate the mutations with the death rate since this scenario is changing constantly. We referenced these in the introduction.
Data Availability
All the sequence data were taken from the GISAID (https://www.gisaid.org/) and RCSB PDB (https://www.rcsb.org/) as mentioned in the methodology section. We provide all the necessary information such as accession numbers, date-based data source for helping readers and reviewers to check the authencity of the work.
